FeedPosted Dec 11th 2009 11:40AM by Mark Fightmaster (RSS feed)
Filed under: Good news, Products and Services, Lilly (Eli) (LLY)

Biogen Idec (
BIIB) has made a bit of news the past two days, starting with Thursday's news that
William Young is the company's new chairman of the board. BIIB's Bruce Ross will complete his term as director and will step down from the board at BIIB's 2010 shareholder meeting. William Young will take over effective January 1, 2010. Young is a veteran of the biotech industry, as he served with Monogram Biosciences, Genentech (where he was CEO), and Eli Lilly.
Ross noted, "I am pleased the Board has selected Bill Young as Biogen Idec's new Chairman. He is an experienced biotechnology and pharmaceutical industry executive with an extensive understanding of Biogen Ides, given his 12 years of service as a director of the company."
Continue reading Biogen Idec names new chairman, announces positive drug test results
Posted Dec 2nd 2009 1:40PM by Sheldon Liber (RSS feed)
Filed under: Management, General Electric (GE), PepsiCo (PEP), Intel (INTC), McDonald's (MCD), International Business Machines (IBM), 3M Corporation (MMM), American Express (AXP), FedEx Corp (FDX), General Mills (GIS), Procter and Gamble (PG), Lockheed Martin (LMT), Lilly (Eli) (LLY), Deere and Co (DE), Unilever ADR (UL), Serious Money, Stock Screen, China Mobile Limited (CHL),
This is the third screening to find value among Fortune's 25 corporate world leaders that have demonstrated an ability to regenerate themselves from within. The list has been cut to 18 and will be cut further here.
The methodology of using basic stock data points to identify potential value investments only sets the stage for success -- it assures nothing. While it is true that paying less is better than paying more and getting a higher yield is better than less, this gives you a scant picture of what is in people's hearts and minds, and that is harder to judge. Like the weather, no matter the predictions, you may not find out it is raining until you are standing in it. Regardless, it should be advantageous to start with good stock (pun intended) before you take to whittlin', and that we have.
Continue reading Serious Money: Fortune's 25 leaders, 18 remain
Posted Dec 1st 2009 6:00PM by Sheldon Liber (RSS feed)
Filed under: General Electric (GE), PepsiCo (PEP), Intel (INTC), McDonald's (MCD), International Business Machines (IBM), 3M Corporation (MMM), American Express (AXP), Colgate-Palmolive (CL), FedEx Corp (FDX), General Mills (GIS), Procter and Gamble (PG), Lockheed Martin (LMT), Lilly (Eli) (LLY), Deere and Co (DE), Unilever ADR (UL), Serious Money, Stock Screen, China Mobile Limited (CHL)
Yesterday I started a review of 25 companies that Fortune deemed most successful according to their peers in developing quality leadership. Today I review the remaining 20, searching to find the ones that might be worth investing in.
Price-to-book (from 11/27/09) was used as the first value screen. The theory being from a value investor's perspective that buying for a price at or near the break-up value of the company provides downside protection. Of course that is easier said than done.
Continue reading Serious Money: Fortune's 25 leaders, now 20
Posted Nov 30th 2009 1:00PM by Sheldon Liber (RSS feed)
Filed under: International Markets, Management, General Electric (GE), PepsiCo (PEP), Intel (INTC), McDonald's (MCD), International Business Machines (IBM), 3M Corporation (MMM), Johnson and Johnson (JNJ), American Express (AXP), Colgate-Palmolive (CL), FedEx Corp (FDX), General Mills (GIS), Procter and Gamble (PG), Lockheed Martin (LMT), Lilly (Eli) (LLY), Deere and Co (DE), Unilever ADR (UL), Serious Money, Stock Screen, China Mobile Limited (CHL),
The recent issue of Fortune magazine discusses how the best of the best train, guide and nurture top managers to become the leaders that will propel their corporations successfully forward. They list the top 25 companies, which I have used as the basis of a new review to see how they would fair against common metric screens.
In the past few months, many articles have posited that large-cap stocks should excel in the coming year based on their lagging the market behind smaller, more volatile stocks flying out of the March lows. I do not believe this is universally true. Plenty of large-cap stocks did well, such as Anadarko Petroleum (APC), Apple (AAPL) and Google (GOOG), while many small caps went nowhere. Even among the large caps included in Fortune's "Leadership 25," some have doubled.
Continue reading Serious Money: Fortune's 25 leaders among leaders
Posted Nov 23rd 2009 10:00AM by Jim Cramer (RSS feed)
Filed under: Analyst Reports, Pfizer (PFE), Market Matters, Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Deere and Co (DE), Stocks to Buy, Potash Corp. of Saskatchewan (POT)
TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all. Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (
MRK) (
Cramer's Take), Bristol-Myers (
BMY) (
Cramer's Take) and Lilly (
LLY) (
Cramer's Take). But there is one drug stock that is continually met with skepticism -- Sanofi Aventis (
SNY) (
Cramer's Take), the French vaccine and pharmaceutical maker run by Christian Viehbacher. The resistance is obvious, as his biggest two drugs are coming off patent very soon, and his hope is that by 2013 the company might again reach 2008 levels.
Sounds like there's no reason to buy this one. Sounds like its 4% dividend isn't safe.
Continue reading Cramer on BloggingStocks: Sanofi has lots of upside catalysts
Posted Oct 1st 2009 4:40PM by Joseph Lazzaro (RSS feed)
Filed under: Lilly (Eli) (LLY), Stocks to Buy
Eli Lilly & Co. (NYSE:
LLY) stock has unexpectedly meandered since the
June 8, 2009 Buy recommendation at a price of $34.10, but the aforementioned probably represents selected investor jitters about the likely, federal health care reform legislation.
Ignore those jitters. The major components of health care reform have not been determined as of September 30, 2009, but the pharma calculation remains the same as it was in June. The legislation will be net-positive for major pharmaceutical companies, under the thesis that there will be 30-45 million more U.S. residents regularly - as opposed to sporadically - accessing health care services over the next decade, not including population growth.
Continue reading Lilly's stock meanders, but remains a Buy
Posted Sep 2nd 2009 5:00PM by Steven Halpern (RSS feed)
Filed under: Coca-Cola (KO), Exxon Mobil (XOM), Colgate-Palmolive (CL), Coca-Cola Enterprises (CCE), Procter and Gamble (PG), Lilly (Eli) (LLY)
"While companies have been cutting dividends at an historic pace over the last 24 months, the fact is that there are still quality companies with long histories of paying dividends that represent good long-term investments," says Chuck Carlson, a specialist in companies offering dividend reinvestment plans.
In his top-notch The DRIP Investor he says, "The seven stocks featured here have each been paying a dividend for over 100 years, have raised their dividend annually for at least the last quarter century and offer direct-purchase plans.
Continue reading Seven dividend elites: 100 years of dividends
Posted Aug 12th 2009 10:20AM by Paul Foster (RSS feed)
Filed under: duPont(E.I.)deNemours (DD), Lilly (Eli) (LLY), Options
DuPont (NYSE: DD) closed at $32.57. August 11 DD options were active on volume of 349,770 contracts into today's ex-dividend. DD August option implied volatility of 33; September is at 35; below its 26-week average 43 according to Track Data, suggesting decreasing price movement.
Eli Lilly (NYSE: LLY) closed at $33.18. LLY goes ex dividend today with a 49 cents dividend. On August 11 LLY options were active on volume of 28,953 contracts. LLY August option implied volatility is at 28, September is at 27; below its 26-week average of 31, suggesting decreasing price movement.
Options Update: Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Posted Jul 15th 2009 12:00PM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Cisco Systems (CSCO), Goldman Sachs Group (GS), Palm Inc (PALM), Lilly (Eli) (LLY), Analyst Initiations, PetroChina Co Ltd ADR (PTR), Hunt(J.B.) Transport (JBHT)
Analyst upgrades:
- Deutsche Bank upgraded HealthSouth (NYSE: HLS) and Rehabcare (NYSE: RHB) to Buy from Hold after raising its Post Acute Care sector view to Positive from Neutral. The firm believes volumes and margin leverage can drive better than expected Q2 results and 2009 guidance. The firm raised its target on HealthSouth shares to $16 from $12 and on Rehabcare to $28 from $19.
- Jefferies upgraded Moody's (NYSE: MCO) to Hold from Underperform to reflect stabilizing credit markets and its belief regulatory concerns are overstated. The firm raised its target on shares to $30 from $19.
- Keefe Bruyette upgraded Goldman Sachs (NYSE: GS) to Outperform from Market Perform as it finds the stock inexpensive following the better than expected results. The firm has a $195 target on shares.
- Vale (NASDAQ: VALE) was upgraded to Buy from Neutral at BofA/Merrill.
- CNOOC (NYSE: CEO) was upgraded to Overweight from Equal Weight at Morgan Stanley.
- International Game Tech (NYSE: IGT) was upgraded to Buy from Neutral at Janney Montgomery.
Continue reading Analyst calls: MCO, VALE, GS, CSCO, PALM, LLY, JBHT, PTR
Posted Jun 19th 2009 4:40PM by Melly Alazraki (RSS feed)
Filed under: Pfizer (PFE), Ford Motor (F), Home Depot (HD), Diageo plc (DEO), Best Buy (BBY), Lilly (Eli) (LLY), Harley-Davidson (HOG), Stocks to Buy

Every year I find myself asking the same question: What to get dad for Father's Day. Well, Kiplinger's offers not to get our dads the same old presents -- another tie, another power tool -- but
stocks in companies he probably likes or uses their products. That's a great idea, I thought, and decided to counter with five of my own.
- Kiplinger's suggests: Diageo (NYSE: DEO), the seller of such brands as Johnnie Walker, Smirnoff, Guinness and José Cuervo. Diageo has held up better than most during the recession -- thanks to a balanced portfolio of products, with higher exposure to mid-price, mainstream brands and less exposure to ultra-premium brands. The shares look reasonably priced. At $56.01, Diageo trades at 15 times estimated June 2009 earnings of $3.82 a share. The stock yields 2.8%.
- Another to consider: Molson Coors (NYSE: TAP), the seller of such brands as Coors, Blue Moon, Pilsner and Rickard's. Beer, probably even more so than hard liquor is supposed to hold better during a recession given the cheaper price point. The company's recent quarterly profits more than doubled. The shares trade at 13 times forward earnings of $3.33 and yield 2.2%.
Continue reading Five stocks for Father's Day from Kiplinger's ... and five more
Posted Jun 16th 2009 10:00AM by Jim Cramer (RSS feed)
Filed under: Market Matters, Lilly (Eli) (LLY), Cramer on BloggingStocks
TheStreet.com's Jim Cramer says there'll be a time to buy health care. But wait until the smoke clears. Please don't tell me we are back in the world of no institutional memory again. That all that happened is we dropped enough points to freak everyone out, get the bears out of hibernation and then it is onward and upward. Nothing would shock me, especially the vehemence with which everyone hated the market again Monday.
If you replay what happened, most of the issues stemmed from statements made by the same Europeans that have said no more stimulus is needed, the same Europeans who have been in denial the whole way publicly, but believe me they have been stimulating like mad because their banks are a much larger size relative to their gross domestic product than ours and are in many ways worse off.
Continue reading Cramer on BloggingStocks: Don't fight the Obama phalanx
Posted Jun 8th 2009 6:00PM by Joseph Lazzaro (RSS feed)
Filed under: Lilly (Eli) (LLY), Stocks to Buy

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with the aforementioned in mind,
Eli Lilly & Co. (NYSE:
LLY) is worth a review.
In general, analysts see a 5-7% revenue gain in FY2009 for Lilly, led by growth in sales of branded drugs Cymbalta, Humalog, Cialis, and Alimta. Meanwhile, sales of Zyprexa and Gemzar are likely to decline this year.
Continue reading Time to scoop up some shares of Lilly
Posted May 4th 2009 10:00AM by Jim Cramer (RSS feed)
Filed under: PepsiCo (PEP), Market Matters, Caterpillar (CAT), Abbott Laboratories (ABT), Kellogg Co (K), Clorox Co (CLX), Colgate-Palmolive (CL), Hershey Co (HSY), General Mills (GIS), Kimberly-Clark (KMB), Lilly (Eli) (LLY), Freep't McMoRan Copper (FCX), Cramer on BloggingStocks
TheStreet.com's Jim Cramer suggests watching certain staples for hints that the flight to riskier plays is losing steam. Will the endless "beta" trade out of slow-moving, "safe" drugs and foods and into companies like
Freeport-McMoRan (NYSE:
FCX) (
Cramer's Take) and
Caterpillar (NYSE:
CAT) (
Cramer's Take) ever end?
I think it won't end here, that's for certain, unless your staples stock goes to a 5% yield and the economy's macro data show a further breakdown. If we get some retail sales that are awful and some employment numbers that show a further trashing, then we are going to see a momentary blip up in stocks like
Pepsi (NYSE:
PEP) (
Cramer's Take) and
Clorox (NYSE:
CLX) (
Cramer's Take), but perhaps no more than that.
Continue reading Cramer on BloggingStocks: 'Tells' of the beta trade
Posted Feb 25th 2009 8:56AM by Allan Halprin (RSS feed)
Filed under: Microsoft (MSFT), Yahoo! (YHOO), General Electric (GE), Citigroup Inc. (C), Johnson and Johnson (JNJ), JPMorgan Chase (JPM), Money and Finance Today, Abbott Laboratories (ABT), AFLAC Inc (AFL), American Express (AXP), Bristol-Myers Squibb (BMY), Consolidated Edison (ED), Verizon Communications (VZ), News Corp'B' (NWS), UAL Corp (UAUA), Lilly (Eli) (LLY)
Continue reading 5% dividends you can believe in, is your pension safe? & 9 optimistic people - Today in Money 2/25
Posted Jan 29th 2009 3:15PM by Mark Fightmaster (RSS feed)
Filed under: Earnings Reports, Lilly (Eli) (LLY)
Earlier today, pharmaceutical firm Eli Lilly (NYSE: LLY) announced that it suffered a fourth-quarter loss thanks to charges suffered when purchasing ImClone Systems. Excluding these charges, LLY tallied $1.07 per share in the quarter -- topping analysts' estimates for $1.05 per share. Taking the ImClone acquisition (which cost LLY $4.73 billion in charges) into account, LLY lost $3.31 per share during the quarter. Quarterly revenue checked in at $5.42 billion.
Continue reading Eli Lilly posts quarterly earnings
Next Page »